SYRE Q3 2022 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SYRESpyre Therapeutics, Inc.

$3B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$174,000-87.6% YoY

Gross Profit

-$328,000-188.5% margin

Operating Income

-$19M-10778.7% margin

Net Income

-$18M-10479.3% margin

EPS (Diluted)

$-4.84

QoQ Revenue Growth

-72.2%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$92M

Total Liabilities

$24M

Stockholders' Equity

$68M

Cash & Equivalents

$39M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$174,000	$1M	-87.6%
Gross Profit	-$328,000	-$13M	+97.6%
Operating Income	-$19M	-$20M	+7.6%
Net Income	-$18M	-$20M	+10.2%